manilatimes5h
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...
Zacks.com on MSN12h
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced ...
Exelixis Notified by FDA That Cabozantinib Application Won't Be Discussed at Meeting
Exelixis said it was notified by the Food and Drug Administration that its treatment for advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic will not be discussed at a meeting.
Hosted on MSN12h
FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia
Agios Pharmaceuticals AGIO announced that the FDA has accepted its supplemental new drug application (sNDA) seeking label ...
Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade)
Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...
The Financial Express15h
USFDA gives nod to Lupin’s generic formulation to treat eye issues
Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of USD 36 million in the U.S.
Hospitals must develop new protocols as overdose crisis enters dangerous new phase with ‘rhino tranq’
To address this evolving crisis, we must dramatically expand rapid access to treatments for addiction and harm reduction ...
Pharmabiz18h
US FDA clears Solid Biosciences’ IND application for SGT-212 to treat neurologic & cardiac manifestations of Friedreich’s ataxia
Charlestown, Massachusetts Thursday, January 9, 2025, 14:30 Hrs [IST] ...